Praluent
PreclinicalSmall molecule
RegeneronPraluent is one of 75 small molecule programs targeting Hyperlipidemia. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
97 competitors in Hyperlipidemia
#DrugCompanyPhaseTrials
1Repatha
AmgenPhase 3
Avapro
SanofiPhase 3
Lorelco
SanofiPhase 3
Praluent
RegeneronPhase 3
Micardis
Boehringer IngelheimPhase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Reyataz
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tricor
JJagotec
Phase 3
Zocor
OOrganon and Co
Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neurocognitive Function1 trial
Treatment1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Praluent. EMBL-EBI & Wellcome Sanger Institute.
- [4]